Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]

Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[2] It was discontinued in 2012.[3]

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
  2. 1 2 "Flanvotumab". Adis Insight. Springer Nature Switzerland AG.
  3. ↑ Williams R (December 2013). "Discontinued drugs in 2012: oncology drugs". Expert Opinion on Investigational Drugs. 22 (12): 1627–1644. doi:10.1517/13543784.2013.847088. PMID 24102323.


source: https://en.wikipedia.org/wiki/Flanvotumab